 |
Prospector
Profile
3-12-002
|
| |
| Achillion Pharmaceuticals, Inc. |
NAICS |
541710 |
| 300 George Street,
New Haven, CT 06511 |
Description |
Biotechnology |
| (203) 624-7000 |
Employees |
60 |
| http://www.achillion.com/ |
Revenue |
(mil) |
4.0400 |
| |
Income |
(mil) |
-28.1000 |
| |
Assets |
(mil) |
35.6300 |
| |
Liability |
(mil) |
14.0900 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Achillion Pharmaceuticals, Inc., reported a net loss of $28.10 million on revenues of $4.04 million for the year ended December 31, 2007, compared to a net loss of $24.09 million on revenues of $3.29 million in the prior year. The Company also used cash for operating activities of $21.03 million during 2006, compared to $29.94 million last year. As a result of its recurring losses, the Company has an accumulated deficit of $151.83 million as of December 31, 2007.
|
| |
|
Intellectual Property:
The Company's elvucitabine patent portfolio currently consists of 7 issued U.S. patents, 25 associated issued non-U.S. patents, 23 associated pending non-U.S. patent applications, and one pending PCT application. The Company either owns or holds exclusive worldwide sublicenses from Vion Pharmaceuticals of patents owned by Yale University or exclusive worldwide licenses from Emory University to these patents and patent applications. Its hepatitis C patent portfolio currently consists of 1 issued U.S. patent, 5 U.S. provisional patent applications, 8 pending U.S. non-provisional applications, 2 associated issued non-U.S. patents, 95 associated pending non-U.S. patent applications and 3 pending PCT applications. In connection with its November 2004 collaboration with Gilead Sciences, the Company granted a worldwide exclusive license to Gilead Sciences for past, present and future patents, patent applications and patent filings with claims directed to the Company's first NS4A antagonists and chemically related compounds, any additional compounds which inhibit HCV via a mechanism similar to that of NS4A antagonism and intellectual property relating to the mechanism of action.
In addition, the Company has obtained non-exclusive licenses to HCV drug discovery patents and patent applications owned by Chiron, a Novartis business unit, Apath, L.L.C. and ReBlikon, GmbH. Its antibacterial patent portfolio currently consists of 8 pending U.S. patent applications, 1 pending U.S. provisional patent application, 38 associated pending non-U.S. applications and 3 pending international patent applications filed under the Patent Cooperation Treaty. [SEC Filing 10-K 03-05-08]
|
| |
|
Description:
Achillion Pharmaceuticals, Inc., engages in the discovery, development, and commercialization of treatments for infectious diseases.
|
| |
|
Officers:
Michael D. Kishbauch (Pres. & CEO); Milind S. Deshpande, Ph.D. (SVP & Chief Scientific Officer); Elizabeth A. Olek, D.O. (SVP & Chief Medical Officer); Gautam Shah, Ph.D. (SVP & Chief Compliance Officer); Mary Kay Fenton (VP & CFO)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock Symbol ACHN; NasdaqGM; 15,638,346 common shares outstanding as of March 1, 2008.
|
| |
| |
| |
| return to main page |
|
|
